Marleau et al. (2012) efficiently delivered trastuzumab to cancer cells and inhibited breast cancer progression by removing HER-2-positive EVs from the entire circulatory system using affinity plasma exchange. The gene discussed is ERBB2; the disease is breast carcinoma.